CION Ameerpet
Pancreatic Cancer · Treatment & Modalities · Reviewed by CION Oncologists
PARP-inhibitor maintenance for BRCA-mutated pancreatic cancer — what it is, and who it is for
A germline BRCA result changes what happens after your chemotherapy has done its work. For a defined group, treatment can switch from an intravenous combination to a targeted tablet taken at home — not to remove the cancer, but to hold it still for longer. This page explains the class plainly: how it works, who it fits, and what it honestly does and does not deliver.
- It is not chemotherapy — it is a targeted tablet that blocks one of the routes a cell uses to repair its own DNA.
- It follows chemotherapy rather than replacing it — the combination has to run its course, and hold the disease, before maintenance begins.
- Only a confirmed germline BRCA change opens this door — which is why NCCN advises genetic testing for everyone with pancreatic adenocarcinoma.
- What it buys is time without growth — a longer quiet interval — not a demonstrated gain in overall life expectancy.
17+
Cancer Specialists
on Panel
on Panel
35+
Centres Across
Telangana & AP
Telangana & AP
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Start here
What “Maintenance” Actually Means Here
Most people arrive here having searched for PARP inhibitor pancreatic cancer, usually within a day or two of a genetic report landing. The word that matters most in that search is the one missing from it: maintenance. This is not an alternative to chemotherapy, and it is not a first move. It is what can sometimes follow chemotherapy, in a defined group of people, once the chemotherapy has already done its work.
The mechanism is worth understanding, because it explains almost everything about who it fits. Cells repair damaged DNA constantly, using more than one route. A pathogenic BRCA1 or BRCA2 change disables one of the main routes — the one that repairs a clean break across both strands accurately. A cancer cell carrying that fault leans harder on the repair routes it has left, and the PARP enzyme sits inside one of them. Block PARP as well, and the cancer cell is left holding damage it cannot fix. Healthy cells, which still have their intact BRCA route, carry on repairing normally. That selectivity is the whole idea.
So this is not a broad pancreatic cancer drug. It is a treatment aimed at one specific inherited fault, in one specific situation, at one specific point in the treatment sequence. If the genetics themselves are what you are trying to make sense of, what a BRCA2 or BRCA1 change means for the pancreas covers that ground properly. This page stays on what happens next.
Did you know? NCCN guidance recommends germline genetic testing for every patient with confirmed pancreatic adenocarcinoma — not only those with a strong family history. Pancreatic cancer is one of the few cancers where testing is advised across the board rather than filtered through family-history criteria, and the decision described on this page is one of the direct reasons why: a germline BRCA result changes the treatment sequence for the patient, and changes what is offered to blood relatives. A clean family history is not a reason to skip the test, and being told you do not need one because nobody else in the family has had cancer is worth questioning.
The sequence
How the Decision Is Actually Reached
Every step has to be in place. A missing one is the usual reason someone who has read about this class is told it does not apply to them.
-
A confirmed tissue diagnosis
The conversation sits on top of a confirmed pancreatic adenocarcinoma, which for most people means a biopsy taken during an endoscopic ultrasound. Imaging alone is not enough to start systemic treatment of this kind.
Biopsy coordinated with specialist endoscopy partners -
Germline testing, with counselling first
The result that opens this option is an inherited change found in a blood or saliva sample and reported after genetic counselling. A change found only inside the tumour is a different conversation, weighed case by case rather than treated as the same finding.
In-house at CION -
Chemotherapy first — and it has to be working
Maintenance is only considered after a defined period of platinum-based combination chemotherapy during which the cancer has not progressed. Chemotherapy for advanced pancreatic cancer explains what that stage involves and how response is judged.
In-house at CION -
A deliberate switch, not a gap
If the disease is stable or shrinking at the end of that period, the intravenous combination can be stopped and the oral maintenance treatment started. The intention is to keep pressure on the cancer while the body gets a rest from combination chemotherapy.
In-house at CION -
Scans and bloods carry on
Maintenance is not a discharge. Imaging and CA 19-9 continue at set intervals, blood counts are checked on a schedule, and treatment continues for as long as it is holding the disease and being tolerated.
In-house at CION
The real choice
Maintenance, More Chemotherapy, or a Planned Break
When induction chemotherapy has run its course, these are the three doors in the room. Maintenance is one of them, not the default.
| Path | What it involves | What it is aiming at | Where it fits |
|---|---|---|---|
| Switch to PARP-class maintenance | An oral targeted treatment taken at home on a daily schedule, with scans, CA 19-9 and blood counts continuing. | Hold the disease still for longer while the body recovers from combination chemotherapy. | Only where a germline BRCA change is confirmed and the cancer has not progressed on platinum-based chemotherapy. |
| Continue the combination chemotherapy | The same intravenous schedule carries on, sometimes with one component dropped or a dose reduced to make it liveable. | Keep the maximum available pressure on the cancer. | Where the combination is clearly working and being tolerated, or where no germline BRCA change is present. |
| A planned treatment break | Active treatment pauses. Scans and CA 19-9 continue on a schedule, and treatment restarts if the disease moves. | Give quality of life back for a defined stretch, with a clear trigger to restart. | Where cumulative side effects have become the dominant problem, or the disease has been quiet for a long period. |
Weighing these three against each other is a decision for a room with your oncologist, your genetic report and your latest scan in it — not for a search results page. Bring all three. Book a free consultation or call 1800 202 8726.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
A Genetic Report Is Only Useful If Someone Reads It With You
Counselling, testing, chemotherapy and maintenance sit under one roof at CION. Start with a free consultation.
Day to day
What Being on Maintenance Actually Involves
The practical shape of this phase, which is usually quieter than the one before it — but not empty.
Taken at home
Tablets, on a fixed daily schedule
Maintenance in this class is oral. There is no infusion chair and no cannula, and most people fit it around ordinary life rather than around hospital visits.
Side effects
Usually lighter than the combination
Tiredness, nausea and a reduced appetite are the common ones. They are generally less punishing than combination chemotherapy, but they are real and worth reporting early rather than enduring quietly.
Blood counts
Monitoring bloods are not optional
This class can lower red cells, white cells and platelets. Routine blood tests are how that is caught before it becomes a problem, which is why the monitoring schedule matters.
Dose adjustment
The dose can be changed
If side effects build up, the first move is usually a dose reduction or a short pause rather than abandoning the treatment. Say something early and there is more room to adjust.
Duration
For as long as it is working
There is no fixed course length. Treatment continues while scans stay stable and side effects stay manageable, and the decision is revisited at every review.
Limits
Not a cure, and not for everyone
It does not remove the cancer, and it does not apply without a confirmed germline BRCA change. Being told it is not an option for you is a statement about your genetics, not about your prognosis.
The honest version
What This Class Does, and What It Does Not
The benefit shown for this class in pancreatic cancer is a longer interval before the cancer starts growing again. That is a genuine benefit and it is worth having: a stretch of time off combination chemotherapy, without infusions, without the heavier side effects, and without the disease advancing. For someone who has just finished months of intravenous treatment, that stretch can matter enormously.
What has not been demonstrated in this cancer is that the class lengthens overall life expectancy. Both of those things can be true at once — a treatment can hold disease still for longer without moving the final outcome — and any oncologist offering you maintenance should say so plainly rather than let you infer more from a hopeful conversation. If nobody has spelt out that distinction to you, ask for it directly, and ask what it means in your own situation specifically.
It also does not replace what comes before or after it. Chemotherapy still does the heavy lifting up front, and if the disease starts moving again the conversation returns to systemic treatment. Maintenance is a phase inside a sequence, not an exit from it. How pancreatic cancer treatment is planned and delivered in Hyderabad sets out where this phase sits in the wider plan, and who does which part of it.
One more honest point. This option depends entirely on a test result. If germline testing has not been offered to you and you have a confirmed pancreatic adenocarcinoma, raise it at your next appointment rather than waiting to be asked — the result takes time to come back, and the decision point arrives at the end of induction chemotherapy whether the report is in the file or not.
What we do
Where CION Fits in This
Set out plainly, including the parts that happen somewhere else, so there is no surprise on a bill.
- A free 45-minute consultation. Long enough to read your genetic report and your latest scan properly, and to say whether maintenance is even on the table for you. Worth booking before you decide anything.
- Genetic counselling and germline testing, in-house. Counselling first, then the test, then an honest reading of the report — including what a variant of uncertain significance does and does not mean for your treatment.
- Chemotherapy and maintenance, delivered by our medical oncology team. Induction combination chemotherapy and PARP-inhibitor-class maintenance are both given in-house, across 35+ CION centres in Telangana and Andhra Pradesh.
- Scans, CA 19-9 and monitoring bloods, ordered and reported here. Pancreatic-protocol CT and MRI/MRCP for response assessment, and the routine blood monitoring this class of treatment requires.
- Nutrition, pancreatic enzyme (PERT) support, pain relief and psycho-oncology. The supportive side of a long treatment phase, alongside the treatment rather than referred away from it.
- Coordinated with partner centres, and may be billed there. The endoscopic ultrasound and EUS-FNA biopsy that confirms the diagnosis, ERCP and biliary or duodenal stenting, staging laparoscopy, coeliac plexus block, PET-CT and DOTATATE PET, PRRT, and all pancreatic surgery are arranged with specialist HPB, gastroenterology and endoscopy partners rather than performed at CION.
If you are still working out where you are in the sequence, the complete pancreatic cancer guide maps the whole pathway from first scan to follow-up. To have your own report read with you, book a free consultation or call 1800 202 8726.
Take the next step
One Test Result Can Change the Sequence
If germline testing has not been offered to you yet, that is worth raising this week. We walk this journey with you.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
PARP-inhibitor maintenance — your questions answered
What is a PARP inhibitor, in plain language?
It is a targeted tablet that blocks one of the routes a cell uses to repair its own DNA. Healthy cells have several repair routes, so blocking one is manageable for them. A cancer cell carrying an inherited BRCA fault has already lost one of the main routes - the one that repairs a clean break across both strands of DNA accurately - so it leans harder on the others. Blocking the PARP route as well leaves that cancer cell holding damage it cannot fix, while normal cells carry on repairing. This is why the class is only used where a BRCA change is genuinely present. Without that fault the selectivity that makes it work simply is not there, and the treatment has no particular advantage over what else is available.
Who is actually eligible for this maintenance treatment?
Four things generally need to line up. First, a confirmed pancreatic adenocarcinoma, usually proven on a biopsy. Second, a pathogenic germline BRCA change, found on a blood or saliva test and reported after genetic counselling, rather than a change found only inside the tumour. Third, a defined period of platinum-based combination chemotherapy already given. Fourth, and most often the sticking point, the cancer must not have progressed during that chemotherapy. If the disease grew through the combination, maintenance with this class is not the next step. Missing any one of those four is the usual reason someone who has read about this treatment is told it does not apply, and it is worth asking your oncologist which of the four is the one that does not fit.
Does a PARP inhibitor cure pancreatic cancer?
No. Nothing on this page should be read as a cure. What this class has been shown to do in pancreatic cancer is lengthen the interval before the disease starts growing again, in the specific group described above. That is a real and worthwhile benefit - time without infusions, without combination chemotherapy side effects, and without the cancer advancing - but it is a narrower claim than the one most people are hoping to read. An overall gain in life expectancy has not been demonstrated for this class in this cancer, and an honest conversation about starting it should include that sentence. If the cancer does start growing again, the plan is reviewed and systemic options are reconsidered.
Do I need a BRCA test even if nobody in my family has had cancer?
Yes, and this surprises many people. NCCN guidance recommends germline genetic testing for every patient with confirmed pancreatic adenocarcinoma, regardless of family history. Pancreatic cancer is one of the few cancers where testing is advised across the board rather than being filtered through family-history criteria. There are two reasons. The result can change your own treatment sequence, because it is what opens the maintenance option described here. And it changes what is offered to your blood relatives, who may become candidates for surveillance if a change is found. A clean family history is not a reason to skip the test, and if it has not been offered to you, ask for it directly.
What is the difference between a germline and a somatic BRCA change?
A germline change is inherited. It is present in every cell of your body, is found on a blood or saliva test, and can be passed to children and shared with siblings. A somatic change has arisen inside the tumour itself during a person's life. It is found on tumour testing, it is not inherited, and it carries no implication for relatives. The distinction matters here because the maintenance decision on this page rests on a germline result. Where only a somatic change is found, or where the report describes a variant of uncertain significance, the situation is weighed case by case rather than treated as the same finding. Your report should state clearly which kind of testing was done.
What are the side effects, and how are they handled?
The common ones for this class are tiredness, nausea and a reduced appetite. Most people find them lighter than the combination chemotherapy that came before, but lighter is not nothing, and they can accumulate over a long treatment phase. The class can also lower red cells, white cells and platelets, which is why routine blood monitoring is part of the schedule rather than an optional extra. When side effects build, the usual first response is a dose reduction or a short pause rather than stopping altogether, so reporting a problem early tends to protect the treatment rather than end it. Nutrition support, pancreatic enzyme support and anti-sickness measures are part of the same plan.
What does CION do for this, and what happens at the first visit?
The first visit is a free 45-minute consultation with a medical oncologist. Bring your genetic report if you have one, your biopsy report, and your most recent scan. We will read them with you and say plainly whether maintenance is on the table, or which step is missing. Genetic counselling and germline testing, induction and maintenance systemic therapy, response scans, CA 19-9 and monitoring bloods, nutrition and enzyme support, pain relief and psycho-oncology are delivered in-house across 35+ CION centres. The endoscopic ultrasound and biopsy, ERCP and stenting, staging laparoscopy, coeliac plexus block, PET-CT and DOTATATE PET, PRRT and all pancreatic surgery are coordinated with specialist partner centres and may be billed there.
Medical disclaimer: This page explains PARP-inhibitor-class maintenance therapy in general terms and is reviewed by a CION medical oncologist with reference to NCCN guidance on pancreatic adenocarcinoma and on germline genetic testing. It deliberately names no molecule, brand or regimen, and states no survival, response or duration figure; whether this class is appropriate for you depends on your own biopsy result, germline test result and response to chemotherapy, and must be decided with your treating team. Genetic counselling and germline testing, chemotherapy and PARP-inhibitor-class maintenance, radiation, chemoradiation and SBRT, pancreatic-protocol CT and MRI/MRCP, CA 19-9 and monitoring bloods, nutrition and pancreatic enzyme (PERT) support, pain relief, psycho-oncology and survivorship care are delivered by CION. Endoscopic ultrasound and EUS-FNA biopsy, ERCP and biliary or duodenal stenting, staging laparoscopy, coeliac plexus block, PET-CT and DOTATATE PET, peptide receptor radionuclide therapy and all pancreatic surgery are coordinated with specialist hepatobiliary, gastroenterology, endoscopy and nuclear medicine partner centres and may be billed there.